Park Avenue Securities LLC Makes New $261,000 Investment in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Park Avenue Securities LLC acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 9,206 shares of the medical equipment provider's stock, valued at approximately $261,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Principal Securities Inc. increased its stake in Smith & Nephew SNATS by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 691 shares in the last quarter. National Bank of Canada FI grew its stake in shares of Smith & Nephew SNATS by 36.5% in the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after buying an additional 446 shares during the period. Hara Capital LLC grew its stake in shares of Smith & Nephew SNATS by 391.4% in the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 1,957 shares during the period. Versant Capital Management Inc increased its position in Smith & Nephew SNATS by 1,970.2% in the 1st quarter. Versant Capital Management Inc now owns 5,217 shares of the medical equipment provider's stock valued at $148,000 after buying an additional 4,965 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its position in Smith & Nephew SNATS by 37.4% in the 4th quarter. Quadrant Capital Group LLC now owns 7,431 shares of the medical equipment provider's stock valued at $183,000 after buying an additional 2,024 shares in the last quarter. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Stock Down 0.4%

Smith & Nephew SNATS stock traded down $0.11 during trading on Thursday, hitting $28.53. 890,947 shares of the company were exchanged, compared to its average volume of 804,309. The business's 50 day moving average is $28.15 and its 200 day moving average is $26.90. Smith & Nephew SNATS, Inc. has a 52 week low of $23.69 and a 52 week high of $31.72. The company has a market capitalization of $12.49 billion, a P/E ratio of 13.21, a PEG ratio of 0.88 and a beta of 0.68. The company has a current ratio of 2.89, a quick ratio of 1.33 and a debt-to-equity ratio of 0.62.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. UBS Group cut Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. Finally, Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $28.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.